Today: 9 June 2026
Digital Turbine stock jumps 20% premarket after outlook raise — what to watch at the open
4 February 2026
2 mins read

Digital Turbine stock jumps 20% premarket after outlook raise — what to watch at the open

New York, Feb 4, 2026, 05:29 EST — Premarket

  • Shares of Digital Turbine jumped roughly 20% in premarket action following its quarterly earnings and an upgraded full-year outlook
  • Revenue rose 12% in the December quarter, pushing the company into a GAAP profit
  • Attention shifts to March-quarter demand indicators and if the rally sticks at the open

Digital Turbine’s shares jumped roughly 20% to $5.93 in premarket action Wednesday. The surge came after the company lifted its full-year revenue and profit forecasts in the wake of its December-quarter report.

The jump matters since Digital Turbine is a small-cap mobile ad-tech player working to restore its growth and cash flow credibility. When guidance changes, the stock usually gaps immediately, then finds its footing afterward.

Investors are keeping an eye on a wider shakeup in app-install advertising and on-device distribution, where budgets shift quickly and competition heats up. The higher forecast seems less about costs and more like a clear sign of growing demand.

Digital Turbine reported fiscal third-quarter revenue of $151.4 million late Tuesday, marking a 12% increase year-over-year. The company posted GAAP net income of $5.1 million, or $0.03 per share. It also raised its fiscal 2026 revenue forecast to between $553 million and $558 million, with a non-GAAP adjusted EBITDA projection of $114 million to $117 million. CEO Bill Stone described the quarter as demonstrating “positive business momentum.” SEC

Adjusted EBITDA excludes interest, taxes, and depreciation, serving as a common gauge of core operating performance. Traders focus on the reconciliation between GAAP and non-GAAP figures, watching closely to see if better results translate into actual cash flow.

During the earnings call, CFO Stephen Lasher revealed total debt dropped over $41 million to $355 million in the quarter. The company also wrapped up its at-the-market share sale program, having sold 6.8 million shares at an average price of $6.54. “We made the decision to terminate our existing at-the-market equity program,” he stated. The Motley Fool

Stone focused on product and distribution, telling analysts a “flywheel” between app-install demand and in-app ads could fuel growth—provided the platform remains integrated. He added that three major mobile game developers signed in December are already using the company’s SingleTap tool, which enables one-click installs, for alternative distribution and “dual downloads” linked to app stores beyond the main channels.

Digital Turbine operates alongside bigger mobile ad-tech firms like AppLovin, battling for performance ad dollars that fluctuate with app-store policies and privacy shifts. Analysts pressed management during the call about evolving competition on iOS and in gaming. Stone responded that the company is gaining share while the market expands at a mid- to high-single-digit rate.

The downside is straightforward. In its most recent quarterly report, Digital Turbine cautioned that both secured and unsecured debt could restrict its financial flexibility. Loan terms and covenants might tighten if operating conditions worsen. The filing also highlights risks tied to industry and economic changes that could dampen ad demand.

Wednesday’s key test: will the premarket surge hold up through the initial liquidity flush, or will it fade as spreads narrow and more traders jump in? Keep an eye on early volume and any broker notes scrutinizing the boosted forecast against March-quarter data.

Stock Market Today

  • Glaukos (GKOS) Shares Show Volatility Amid 19% Undervaluation Claim
    June 9, 2026, 9:42 AM EDT. Glaukos (GKOS) shares rose 18% in the past week but fell nearly 9% over the last month, reflecting short-term volatility. The stock trades at $121.96, below its fair value estimate of $151.08, suggesting a 19.3% undervaluation. The company's focus on ophthalmic therapies, including iDose TR for glaucoma, underpins a potential shift in treatment approaches driven by an aging population and increasing glaucoma cases. Investors consider this a long-term growth opportunity, though realization depends on product adoption and reimbursement policies. Glaukos posted a one-year total shareholder return of 28.87%, indicating sustained momentum despite recent fluctuations. The valuation hinges on expectations of revenue growth, profitability turnaround, and premium earnings multiples typical of high growth firms.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
AmpliTech’s 5G Radio Test Moves AMPG Shares

AmpliTech’s 5G Radio Test Moves AMPG Shares

9 June 2026
AMPG soared 26.7% to $6.57 after AmpliTech revealed its 64T64R Massive MIMO radio was the only one of its kind at O-RAN PlugFest, showing interoperability with major carriers’ equipment, but no new orders were announced, leaving sales conversion as the key investor focus.
Take-Two (TTWO) stock eyes a sharp open after forecast raise, GTA VI date held
Previous Story

Take-Two (TTWO) stock eyes a sharp open after forecast raise, GTA VI date held

Apple stock jumps as Goldman flags App Store spending pickup, keeping AAPL in focus
Next Story

Apple stock jumps as Goldman flags App Store spending pickup, keeping AAPL in focus

Go toTop